痛风患者血尿酸与血脂水平的关系及非布司他的降血脂作用

doi:10.13481/j.1671-587x.20150528

Abstract

Abstract:

Objective To explore the relationship between serum uric acid (UA)and serum lipid levels in the patients with gout and the effect of febuxostat on reducing the serum lipid levels. Methods 60 male patients with gout were chosen as gout group,and 25 healthy controls were chosen as control group.The serum uric acid and lipid levels of the objects were compared between gout and control groups.42 patients with hyperlipidemia in gout group were chosen and divided into three subgroups,such as low dose of febuxostat group (febuxostat 40 mg·d^-1,n=13), high dose of febuxostat group(febuxostat 80 mg·d^-1,n=16),and allopurinol group(allopurinol 300 mg·d^-1,n=13).The double blind method was used.The serum UA and lipid levels of the objects in three subgroups and control group before and after treatment were compared. Results The levels of serum UA,triglycerides (TG),total cholesterol (TC),low density lipoprotein (LDL) of the patients in gout group were higher than those in control group(P<0.05).The level of UA was positively correlated with TG in gout group (r=0.275,P<0.05).Compared with before treatment,the level of high density lipoprotein (HDL) after treatment in low dose of febuxostat group was increased (P< 0.05);compared with control group,the levels of HDL of the patients in low dose of febuxostat group after treatment had no significant difference (P> 0.05).Compared with before treatment,the levels of TC,HDL,LDL,and TG of patients after treatment in high dose of febuxostat group were increased(P< 0.05);Compared with control group,the levels of TC,HDL,LDL and TG of the patients in high dose of febuxostat group after treatment had no significant difference (P> 0.05).There were no significant differences of TC,HDL,LDL,and TG of the patients in allopurinol group between before and after treatment(P> 0.05).Compared with before treatment,the UA levels were decreased after treatment in low dose of febuxostat group,high dose of febuxostat group and allopurinol group (P< 0.05);compared with control group,the UA level of the patients in high dose of febuxostat group had no statistically significant difference (P>0.05). Conclusion The patients with gout are often combined with hyperlipidemia.Febuxostat may lower the levels of serum UA and lipids, and febuxostat (80 mg·d^-1) may reduce the levels of LDL,TC,TG,and increase the level of HDL.

Key words: gout, hyperlipidemia, febuxostat, allopurinol

CLC Number:

ZHANG Jin, LIU Tao, JIANG Zhenyu, YAN Haibo, ZHANG Yandong. Relationship between serum uric acid and lipid levels in patients with gout and effect of febuxostat on reducing serum lipid levels[J].Journal of Jilin University Medicine Edition, 2015, 41(05): 1018-1022.

References

[1] Lawrence RC,Felson DT,Helmick CG,et al.Estimates of the prevalence of arthritis and other rheumatic conditions in the United States:part Ⅱ[J].Arthritis Rheum,2008,58(1):26-35.

[2] Robinson PC,Taylor WJ,Merriman TR.Systematic review of the prevalence of gout and hyperuricaemia in Australia[J].Intern Med J,2012,42(9):997-1007.

[3] Grassi D,Ferri L,Desideri G,et al.Chronic hyperuricemia,uric acid deposit and cardiovascular risk[J].Curr Pharm Design,2013,19(13):2432.

[4] 许海燕,顼志敏,陆宗良.中国成人血脂异常防治指南 (2007) 概要与解读 [J].中华老年心脑血管病杂志,2008,10(3):238-240.

[5] Lu W,Song K,Wang Y,et al.Relationship between serum uric acid and metabolic syndrome:an analysis by structural equation modeling[J].J Clin Lipidol,2012,6(2):159-167.

[6] MarottaT,LiccardoM,SchettiniF,et al.Association of hyperuricemia with conventional cardiovascular risk factors in elderly patients[J].J Clin Hypertens (Greenwich),2015(1):27-32.

[7] Xu J,Peng H,Ma Q,et al.Associations of non-high density lipoprotein cholesterol and traditional blood lipid profiles with hyperuricemia among middle-aged and elderly Chinese people:a community-based cross-sectional study[J].Lipids Health Dis,2014,13(1):117.

[8] Tinahones JF,Perez-Lindon G,C-Soriguer FJ,et al.Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients 1[J].J Clin Endocrinol Metab,1997,82(4):1188-1191.

[9] Choi HK,Ford ES,Li C,et al.Prevalence of the metabolic syndrome in patients with gout:the third national health and nutrition examination survey[J].Arthrit Care Res,2007,57(1):109-115.

[10] Becker MA,Schumacher HR,Espinoza LR,et al.The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout:the confirms trial[J].Arthrit Care Res,2010,12:R63.

[11] Real JT,Martínez-Hervás S,García-García AB,et al.Circulating mononuclear cells nuclear factor-kappa B activity,plasma xanthine oxidase,and low grade inflammatory markers in adult patients with familial hypercholesterolaemia[J].Eur J Pharmacol,2010,40(2):89-94.

[12] Povoa Jr H,Sa LD,Lessa VM.Xanthine oxidase and triglycerides in serum of patients with hyperlipoproteinemia,type Ⅳ[J].Biomed Biochim Acta,1983,43(10):1201-1203.

[13] Sezai A,Soma M,Nakata K,et al.Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial)[J].Circ J,2013,77(8):2043-2049.

[14] Sánchez-Lozada LG,Tapia E,Bautista-García P,et al.Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome[J].Am J PhysiolRenal,2008,294(4):F710-F718.

[15] Reungjui S,Roncal CA,Mu W,et al.Thiazide diuretics exacerbate fructose-induced metabolic syndrome[J].J Am Soc Nephrol,2007,18(10):2724-2731.

[16] Ziga N,Becic F.Allopurinol effect on values of lipid profile fractions in hyperuricemic patients diagnosed with metabolic syndrome[J].Mater Sociomed,2013,25(3):167.

[17] Okamoto K,Eger BT,Nishino T,et al.An extremely potent inhibitor of xanthine oxidoreductase crystal structure of the enzyme-inhibitor complex and mechanism of inhibition[J].J Biol Chem,2003,278(3):1848-1855.

[18] 时佳,沈震,苗慧,等.血脂水平与慢性丙型肝炎患者抗病毒疗效的相关性分析[J].临床肝胆病杂志,2014,30(6):496-500.

Relationship between serum uric acid and lipid levels in patients with gout and effect of febuxostat on reducing serum lipid levels

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	FAN Hairui, ZHAO Yan, FU Jinglong, ZHANG Haibo, WANG Dechao, GAO Yugang, ZHANG Lianxue. Improvement effects of Tongfengning Capsule on pathological injuries of major organs in gouty nephropathy model mice [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 741-745.
[2]	FAN Hairui, ZHAO Yan, FU Jinglong, ZHANG Haibo, WANG Dechao, GAO Yugang, ZHANG Lianxue. Anti-inflammatory effect of Tongfengning Capsule in rats with acute gouty arthritis and its mechanism [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 270-274.
[3]	DAI Huining, LYU Shuai, WANG Deli, LI Dan, ZHANG Shitao, LIU Jianing, LIU Yang, LIU Xiaobo, LI Wannan. Therapeutic effect of sunflower powder active ingredients on hyperuricemia in mice [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 327-331.
[4]	GONG Xilong, YANG Guang, SUN Hongbin, WANG Yueshu. Analysis of clinical effect of surgical treatment in patients with multiple tophi in extremities: A report of 23 cases [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 394-397.
[5]	YAN Haibo, MA Ning, CUI Chunli, LIU Tao, ZHAO Ling, JIANG Zhenyu. Curative effect of febuxostat in treatment of gouty arthritis and its safety evaluation [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 135-140.
[6]	ZHAO Yan, HAN Lingling, HOU Yingying, GUO Shuai, TANG Guosheng, ZHANG Lianxue. Hypolipidemic effect of ethanol from Epimedium brevicornu Maxim on hyperlipidemia of mice and its antioxidant activity [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 1-5.
[7]	DU Biao, XIE Xingxing, ZHANG Jie, FAN Xiaodong, YE Yun. Systematic review of efficacy and safety of rosuvastatin in treatment of patients with primary hyperlipidemia in China [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 968-974.
[8]	YUAN Sheng, SHAO Shuyan, YANG Guang, ZHANG Ju. A case report of gout arthritis in second metatarsophalangeal joint complicated with congenital brachydactyly [J]. Journal of Jilin University Medicine Edition, 2016, 42(03): 574-576.
[9]	XIE Hui-chen,LIU Fen,YANG Qiang. Regulation and inhibition of lipid-lowering mixture on blood lipid and blood flow abnormalities of hyperlipemia rats [J]. J4, 2012, 38(5): 937-942.
[10]	JIANG Tong-Wei, XU Jian, WANG Xiao-Meng, CHEN Xue-Song, QIU Zhi-Dong. Screening of \|active ingredient of Stigmata maydis inhibitrg \|xanthine oxidase \|and its \|effect [J]. J4, 2011, 37(3): 433-436.
[11]	LU Ying, WU Wen-Jie, LIU Ya, LI Hong-Yan, ZHANG Gui-Ying, WANG Xue. Protective effect of exogenous zinc sulfate on liver injury of diabetic rats [J]. J4, 2010, 36(5): 871-874.
[12]	YANG Wen, ZHANG Yan-Hua, SHA Chun-Rui. Changes of homocysteic acid and C-reactive protein levels in blood plasma of elderly patients with coronary heart disease and their clinical significances [J]. J4, 2009, 35(6): 1115-1118.
[13]	SUN Xiao,JIANG En-ping,CHEN Jian-guang. Protective effect of Schizandrae Lignanoid on 　myocardial ischemia-reperfusion injury　 in hyperlipidemic rats and its mechanism [J]. J4, 2009, 35(2): 276-279.
[14]	WANG Da-wei,XU Xiu-ying,LIU Ting-ting. Action of corn filament beverage on falling blood fat in hyperlipemia rats and mice [J]. J4, 2007, 33(6): 1029-1032.
[15]	QU Ji-bing, BAO Xue-ying , ZHANG Ming, DU Hong-wei, LIU Yan-jun. Effect of oxidized low-density lipoprotein on endothelium-dependent relaxation in hyperlipidemic patients [J]. J4, 2006, 32(6): 1055-1058.